RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.
12 Articles in this Series
Introduction
Central Post-Stroke Pain – How Central Is It?
False-Positive Urine Drug Monitoring Results and Aspirin
Medical Marijuana & Pain
More Potential Uses for Low-Dose IV Naloxone
On the Horizon: A Brief Look at Potential Analgesics of the Future
Preview of PAINWeek 2018 - Know Before You Go
Stem Cells & Beyond
Underlying Causes of Small Fiber Neuropathies
Understanding Sexual Pain – A Physical Therapist’s Perspective
Video: Drs. Gudin & Fudin on PAINWeek 2018 and PPM's Future
Where Does the Patient-Centered Pain Practitioner Stand Today?
Why Interventional Tactics Should be Used for Chronic Pain Patients Now, Not Later

On the Horizon: A Brief Look at Potential Analgesics of the Future

At PAINWeek 2018 in Las Vegas, Jeff Gudin, MD, director of pain management and palliative care at Englewood Hospital and Medical Center, in New Jersey, and Co-Editor-At-Large of PPM, shared insight into novel analgesics that are either proving intriguing and successful in research or emerging into the marketplace. Among the noteworthy products and targets:

Opioid Products

  • Abuse-deterrent formulations
  • Slow-entry formulations
  • Partial agonists
  • Opioid-like molecules
  • Biased opioid ligands
  • Kappa opioid receptor agonists
  • Prodrugs

Non-Opioid Products

  • Alpha2 adrenergic agonists
  • NMDA receptor agonists
  • Gabapentinoids
  • Novel NSAIDS
  • Nerve growth factor (NGF) antagonists (read more)
  • Glial cell modulators
  • Cannabinoids
  • Topicals, specifically new formulations and technologies that offer improved delivery

Watch for PPM in-depth coverage on each of these novel analgesics in the coming months.

Next summary: Preview of PAINWeek 2018 - Know Before You Go
close X
SHOW MAIN MENU
SHOW SUB MENU